Dynavax Technologies (NASDAQ:DVAX) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet
H.C. Wainwright Maintains Dynavax Technologies(DVAX.US) With Buy Rating, Maintains Target Price $29
H.C. Wainwright analyst Edward White maintains $Dynavax Technologies(DVAX.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 28
Dynavax Reports First Participant Dosed in Shingles Vaccine Trial
Dynavax Technologies (DVAX) said late Thursday the first participant has been dosed in its phase 1/2 study of its vaccine candidate Z-1018 to prevent shingles, a disease caused by the varicella-zoster
Express News | Dynavax Initiates Phase 1/2 Study Of Novel Shingles Vaccine Program Evaluating Safety, Tolerability And Immunogenicity Of Z-1018
Express News | Dynavax Technologies Corp: Anticipates Reporting Top Line Immunogenicity and Safety Data in Second Half of 2025
Express News | Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
Dynavax, Bloomin Brands, and Premier Are the Most Shorted Small-cap Stock in May - Hazeltree Report
Dynavax Technologies(DVAX.US) Director Sells US$43,126.95 in Common Stock
$Dynavax Technologies(DVAX.US)$ Director CANO FRANCIS sold 3,615 shares of common stock on May 31, 2024 at an average price of $11.93 for a total value of $43,126.95.Source: Announcement What is state
Dynavax to Present at Upcoming Investor Conferences
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...
Dynavax Technologies' (NASDAQ:DVAX) Soft Earnings Are Actually Better Than They Appear
The most recent earnings report from Dynavax Technologies Corporation (NASDAQ:DVAX) was disappointing for shareholders. Despite the soft profit numbers, our analysis has optimistic about the overall
Dynavax Down 5% on FDA Complete Response Letter for Heplisav-B for Hemodialysis
UPDATE 1-US FDA Declines to Approve Expanded Use of Dynavax's Hepatitis B Vaccine
Dynavax Application for Hepatitis B Treatment Ruled Insufficient by FDA
By Denny Jacob Dynavax disclosed that the Food and Drug Administration has ruled its application for its hepatitis B vaccine treatment didn't provide sufficient data to support the full evaluation of
Express News | Shares of Dynavax Down 7.9% Premarket After FDA Declines Expanded Use of Its Hepatitis B Vaccine in Dialysis Patients
Express News | FDA Issued Complete Response Letter To Dynavax Saying SBLA For Four-Dose HEPLISAV-B Regimen Did Not Provide Sufficient Data To Support Full Evaluation Of Effectiveness Or Safety
Express News | Dynavax Technologies:Crl Does Not Affect Approval From European Commission in Oct 2023 for 4-Dose Heplisav-B Regimen for Adult Hemodialysis Population
Express News | Dynavax: Crl States Application Did Not Provide Sufficient Data to Support Full Evaluation of Effectiveness or Safety of 4-Dose Regimen of Heplisav-B
Express News | Dynavax Technologies Corp: FDA Has Issued Crl in Response to Sbla
Express News | Dynavax Provides Regulatory Update on Sbla for Four-Dose Heplisav-B® Regimen for Adults on Hemodialysis in the U.S.
Dynavax Technologies (NASDAQ:DVAX) Shareholders Are Still up 78% Over 5 Years Despite Pulling Back 7.8% in the Past Week
It hasn't been the best quarter for Dynavax Technologies Corporation (NASDAQ:DVAX) shareholders, since the share price has fallen 13% in that time. But at least the stock is up over the last five y